Logo image of ALDX

ALDEYRA THERAPEUTICS INC (ALDX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ALDX - US01438T1060 - Common Stock

4.54 USD
-0.05 (-1.09%)
Last: 12/12/2025, 8:13:41 PM
4.75 USD
+0.21 (+4.63%)
Pre-Market: 12/15/2025, 4:00:00 AM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ALDX. ALDX was compared to 529 industry peers in the Biotechnology industry. While ALDX seems to be doing ok healthwise, there are quite some concerns on its profitability. ALDX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ALDX had negative earnings in the past year.
ALDX had a negative operating cash flow in the past year.
In the past 5 years ALDX always reported negative net income.
ALDX had a negative operating cash flow in each of the past 5 years.
ALDX Yearly Net Income VS EBIT VS OCF VS FCFALDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

ALDX has a Return On Assets of -55.52%. This is comparable to the rest of the industry: ALDX outperforms 45.18% of its industry peers.
The Return On Equity of ALDX (-87.71%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -55.52%
ROE -87.71%
ROIC N/A
ROA(3y)-37.64%
ROA(5y)-36.54%
ROE(3y)-50.36%
ROE(5y)-48.45%
ROIC(3y)N/A
ROIC(5y)N/A
ALDX Yearly ROA, ROE, ROICALDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ALDX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALDX Yearly Profit, Operating, Gross MarginsALDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

ALDX has more shares outstanding than it did 1 year ago.
ALDX has more shares outstanding than it did 5 years ago.
ALDX has a worse debt/assets ratio than last year.
ALDX Yearly Shares OutstandingALDX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
ALDX Yearly Total Debt VS Total AssetsALDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -4.01, we must say that ALDX is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of ALDX (-4.01) is comparable to the rest of the industry.
ALDX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.01
ROIC/WACCN/A
WACCN/A
ALDX Yearly LT Debt VS Equity VS FCFALDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M 200M

2.3 Liquidity

ALDX has a Current Ratio of 2.72. This indicates that ALDX is financially healthy and has no problem in meeting its short term obligations.
ALDX has a worse Current ratio (2.72) than 69.00% of its industry peers.
ALDX has a Quick Ratio of 2.72. This indicates that ALDX is financially healthy and has no problem in meeting its short term obligations.
ALDX has a worse Quick ratio (2.72) than 67.30% of its industry peers.
Industry RankSector Rank
Current Ratio 2.72
Quick Ratio 2.72
ALDX Yearly Current Assets VS Current LiabilitesALDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

ALDX shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 2.67%.
EPS 1Y (TTM)2.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ALDX will show a very strong growth in Earnings Per Share. The EPS will grow by 27.40% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y69.8%
EPS Next 2Y20.95%
EPS Next 3Y29.59%
EPS Next 5Y27.4%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALDX Yearly Revenue VS EstimatesALDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2023 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M
ALDX Yearly EPS VS EstimatesALDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 -1 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ALDX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ALDX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALDX Price Earnings VS Forward Price EarningsALDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALDX Per share dataALDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

A more expensive valuation may be justified as ALDX's earnings are expected to grow with 29.59% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.95%
EPS Next 3Y29.59%

More info and screens

0

5. Dividend

5.1 Amount

ALDX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

ALDEYRA THERAPEUTICS INC

NASDAQ:ALDX (12/12/2025, 8:13:41 PM)

Premarket: 4.75 +0.21 (+4.63%)

4.54

-0.05 (-1.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2025-11-05/amc
Earnings (Next)02-26 2026-02-26/amc
Inst Owners57.33%
Inst Owner Change11.89%
Ins Owners2.93%
Ins Owner Change0.05%
Market Cap273.13M
Revenue(TTM)N/A
Net Income(TTM)-43.19M
Analysts86.67
Price Target9.86 (117.18%)
Short Float %10.49%
Short Ratio8.22
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)41.76%
Min EPS beat(2)35.53%
Max EPS beat(2)47.98%
EPS beat(4)3
Avg EPS beat(4)26.62%
Min EPS beat(4)-17.52%
Max EPS beat(4)47.98%
EPS beat(8)5
Avg EPS beat(8)4.2%
EPS beat(12)9
Avg EPS beat(12)14.09%
EPS beat(16)13
Avg EPS beat(16)13.7%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1.75%
EPS NQ rev (1m)32.79%
EPS NQ rev (3m)35.43%
EPS NY rev (1m)40.57%
EPS NY rev (3m)40.57%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.55
P/tB 5.55
EV/EBITDA N/A
EPS(TTM)-0.73
EYN/A
EPS(NY)-0.5
Fwd EYN/A
FCF(TTM)-0.67
FCFYN/A
OCF(TTM)-0.67
OCFYN/A
SpS0
BVpS0.82
TBVpS0.82
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -55.52%
ROE -87.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-37.64%
ROA(5y)-36.54%
ROE(3y)-50.36%
ROE(5y)-48.45%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.72
Quick Ratio 2.72
Altman-Z -4.01
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48%
EPS Next Y69.8%
EPS Next 2Y20.95%
EPS Next 3Y29.59%
EPS Next 5Y27.4%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y8.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year8.9%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y4.7%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4.7%
OCF growth 3YN/A
OCF growth 5YN/A

ALDEYRA THERAPEUTICS INC / ALDX FAQ

What is the fundamental rating for ALDX stock?

ChartMill assigns a fundamental rating of 2 / 10 to ALDX.


What is the valuation status for ALDX stock?

ChartMill assigns a valuation rating of 1 / 10 to ALDEYRA THERAPEUTICS INC (ALDX). This can be considered as Overvalued.


What is the profitability of ALDX stock?

ALDEYRA THERAPEUTICS INC (ALDX) has a profitability rating of 1 / 10.